ASCO Annual Meeting
Annual Meeting of American Society of Clinical Oncology (ASCO)
Chicago, June 1 - June 5, 2012
- Roche’s targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III trial read more
- Roche data showed that people with metastatic colorectal cancer lived longer when they continued on Avastin plus chemotherapy read more
- Roche study showed that adding Avastin to chemotherapy cut the risk of the disease getting worse in difficult-to-treat recurrent ovarian cancer by half read more
- Roche Analyst Event at ASCO 2012 read more
Analyst briefing on data presented at ASCO: Sunday, June 3
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (1-5 June 2012).
We will have a significant presence at the congress with almost 300 scientific abstracts submitted.
A summary of the key data presented at ASCO will be provided at the Analyst briefing.
- Trastuzumab emtansine (T-DM1) in HER2-positive locally advanced or metastatic breast cancer, EMILIA study
Kimberly Blackwell, MD, Professor of Medicine, Assistant Professor in Radiation Oncology, Duke University School of Medicine, Division of Medicine - Oncology
- Oncology pipeline update
Hal Barron, M.D., Chief Medical Officer and Head, Global Product Development
- Oncology business and strategy update
Pascal Soriot, COO Roche Pharmaceuticals Division